Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (NY: BHC )

6.540 -0.800 (-10.90%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,314,650
Open 7.300
Bid (Size) 6.600 (2)
Ask (Size) 6.690 (5)
Prev. Close 7.340
Today's Range 6.540 - 7.330
52wk Range 3.960 - 11.46
Shares Outstanding 358,808,755
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health Provides Update on Strategic Alternatives
Via ACCESS Newswire
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-17.63%
-17.63%
1 Month
-16.69%
-16.69%
3 Month
-30.57%
-30.57%
6 Month
+19.34%
+19.34%
1 Year
-19.46%
-19.46%

More News

Read More
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Via ACCESS Newswire
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
Via ACCESS Newswire
Bausch Health Announces Third Quarter 2024 Results
Via ACCESSWIRE
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
Via ACCESSWIRE
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Via ACCESSWIRE
Bausch Health Appoints New Chief Medical Officer and Head of R&D
Via ACCESSWIRE
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Via ACCESSWIRE
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
Via ACCESSWIRE
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Via ACCESSWIRE
Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
Via Benzinga
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
Via Benzinga
Topics Bankruptcy Stocks
Exposures Financial Legal US Equities
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Via Benzinga
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
Via ACCESSWIRE
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Via ACCESSWIRE
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Topics Economy
Exposures Interest Rates
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Via Investor's Business Daily
Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens
Via Benzinga
Topics Economy
Exposures Interest Rates
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.